Alan F. Schatzberg, M.D.
Stanford University School of Medicine
Scientific Council Member (Joined 2005)
2005 Falcone Prizewinner for Outstanding Achievement in
Affective Disorders Research (Colvin…
Read More
A small study of intravenous ketamine treatment for adolescents with treatment-resistant depression indicates that the drug may be an effective treatment for at least some teens, according to a new…
Read More
The experimental drug esketamine rapidly reduced thoughts of suicide and symptoms of depression in a small clinical trial reported April 16 in the American Journal of Psychiatry.
Read More
A single dose of ketamine, the anesthetic drug that has been found to have fast-acting antidepressant effects, can significantly reduce suicidal thoughts in patients with depression for up to a week…
Read More
Thoughts of suicide in patients with bipolar disorder declined significantly within 24 hours following treatment with ketamine, according to a small randomized trial reported April 28 in the journal…
Read More
